Schering Plans Bridion Clinical Trial To Address FDA’s Hypersensitivity Concerns
This article was originally published in The Pink Sheet Daily
Executive Summary
Company expects to initiate the trial for the novel anesthesia injection this year.
You may also be interested in...
Merck On Track To File Novel Sleep Aid Suvorexant In 2012
Merck announced its potential first-in-class dual orexin receptor antagonist suvorexant successfully completed a second Phase III trial, apparently without safety concerns that led Actelion/GlaxoSmithKline to drop their DORA almorexant a year ago on Phase III results.
Merck On Track To File Novel Sleep Aid Suvorexant In 2012
Merck announced its potential first-in-class dual orexin receptor antagonist suvorexant successfully completed a second Phase III trial, apparently without safety concerns that led Actelion/GlaxoSmithKline to drop their DORA almorexant a year ago on Phase III results.
Schering’s Organon Grab Made Merck's Merger Magic Happen
Takeover in 2007 proved no permanent fix for Schering, but it was enough to lure an even bigger deal.